)

Y-mAbs Therapeutics (YMAB) investor relations material
Y-mAbs Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Entered into a definitive merger agreement with Perseus BidCo US, Inc. and SERB Pharmaceuticals for a cash tender offer at $8.60 per share, with the company to become a wholly owned subsidiary upon completion; deal valued at $412 million and expected to close by Q4 2025.
DANYELZA remains the only FDA-approved product, with ongoing clinical trials and expansion into new indications and geographies.
Business realignment in January 2025 led to a 12% workforce reduction, operational restructuring into two segments, and reduced personnel and compensation costs.
Cash and cash equivalents stood at $62.3 million as of June 30, 2025.
Financial highlights
Q2 2025 revenues were $19.5 million, down 14% year-over-year but exceeding guidance, mainly due to lower DANYELZA sales in the US and ex-US markets.
Net loss for Q2 2025 was $3.2 million, or ($0.07) per share, improved from $9.2 million or ($0.21) per share in Q2 2024.
Gross margin for Q2 2025 was 86%.
Operating expenses declined due to lower R&D and SG&A costs, including the absence of prior year litigation settlements.
Interest and other income rose to $2.3 million, mainly from foreign currency gains.
Outlook and guidance
Cash position projected to support operations as currently planned into 2028, assuming no merger completion.
Ongoing clinical trials for DANYELZA and SADA PRIT platform, with key studies expected to complete enrollment or report results by 2028.
Manufacturing transition for DANYELZA to Italy in 2026 may temporarily increase costs and inventory levels.
Transaction with SERB expected to close by Q4 2025, pending tender offer and regulatory approvals.
Next Y-mAbs Therapeutics earnings date

Next Y-mAbs Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage